Business Context and Reporting Period
Company: Syndax Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date: December 14, 2022
Event: Closing of an underwritten public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial results. Specific metrics include:
- Shares Issued: 7,840,909 shares of common stock.
- Offering Price: $22.00 per share.
- Underwriter Option: Fully exercised for 1,022,727 additional shares.
- Total Shares Outstanding: 68,100,918 shares as of December 14, 2022.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. These operational metrics are not disclosed in this specific 8-K report.
Material Changes
The primary material change is the increase in outstanding share count and the influx of capital from the public offering. The company moved from its pre-offering share count to 68,100,918 shares issued and outstanding following the closing.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the standard legal disclaimers regarding the press release. The document serves primarily to disclose the completion of the transaction.
Investor Verification Checklist
- Verify the total gross proceeds raised by multiplying the 7,840,909 shares by the $22.00 offering price.
- Confirm the updated share count of 68,100,918 in subsequent filings or stock exchange data.
- Review the attached Press Release (Exhibit 99.1) for details on the intended use of proceeds, which are not detailed in the 8-K text itself.
- Check for any dilution impact on existing shareholders based on the new share count.